370 related articles for article (PubMed ID: 24771645)
1. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.
Wynes MW; Hinz TK; Gao D; Martini M; Marek LA; Ware KE; Edwards MG; Böhm D; Perner S; Helfrich BA; Dziadziuszko R; Jassem J; Wojtylak S; Sejda A; Gozgit JM; Bunn PA; Camidge DR; Tan AC; Hirsch FR; Heasley LE
Clin Cancer Res; 2014 Jun; 20(12):3299-309. PubMed ID: 24771645
[TBL] [Abstract][Full Text] [Related]
2. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
[TBL] [Abstract][Full Text] [Related]
3. A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines.
Ren S; Rivard CJ; Yu H; Genova C; Rozenboom L; Gao D; Hinz TK; Rikke BA; Wynes MW; Caldwell C; Agustoni F; Kenichi Suda ; Jiang T; Zhou C; Heasley LE; Hirsch FR
Clin Lung Cancer; 2018 Sep; 19(5):450-456. PubMed ID: 30146263
[TBL] [Abstract][Full Text] [Related]
4. Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.
Singleton KR; Hinz TK; Kleczko EK; Marek LA; Kwak J; Harp T; Kim J; Tan AC; Heasley LE
Cancer Res; 2015 Oct; 75(20):4398-406. PubMed ID: 26359452
[TBL] [Abstract][Full Text] [Related]
5. FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers.
Göke F; Franzen A; Hinz TK; Marek LA; Yoon P; Sharma R; Bode M; von Maessenhausen A; Lankat-Buttgereit B; Göke A; Golletz C; Kirsten R; Boehm D; Vogel W; Kleczko EK; Eagles JR; Hirsch FR; Van Bremen T; Bootz F; Schroeck A; Kim J; Tan AC; Jimeno A; Heasley LE; Perner S
Clin Cancer Res; 2015 Oct; 21(19):4356-64. PubMed ID: 26015511
[TBL] [Abstract][Full Text] [Related]
6. Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1.
Ren M; Hong M; Liu G; Wang H; Patel V; Biddinger P; Silva J; Cowell J; Hao Z
Oncol Rep; 2013 Jun; 29(6):2181-90. PubMed ID: 23563700
[TBL] [Abstract][Full Text] [Related]
7. Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib.
Ng TL; Yu H; Smith DE; Boyle TA; York ER; Leedy S; Gao D; Aisner DL; Van Bokhoven A; Heasley LE; Hirsch FR; Camidge DR
Clin Lung Cancer; 2019 Jan; 20(1):e39-e51. PubMed ID: 30297175
[TBL] [Abstract][Full Text] [Related]
8. Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma.
Marek LA; Hinz TK; von Mässenhausen A; Olszewski KA; Kleczko EK; Boehm D; Weiser-Evans MC; Nemenoff RA; Hoffmann H; Warth A; Gozgit JM; Perner S; Heasley LE
Mol Cancer Res; 2014 Oct; 12(10):1460-9. PubMed ID: 24966347
[TBL] [Abstract][Full Text] [Related]
9. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.
Wang R; Wang L; Li Y; Hu H; Shen L; Shen X; Pan Y; Ye T; Zhang Y; Luo X; Zhang Y; Pan B; Li B; Li H; Zhang J; Pao W; Ji H; Sun Y; Chen H
Clin Cancer Res; 2014 Aug; 20(15):4107-14. PubMed ID: 24850843
[TBL] [Abstract][Full Text] [Related]
10. Characterization of fibroblast growth factor receptor 1 in small-cell lung cancer.
Thomas A; Lee JH; Abdullaev Z; Park KS; Pineda M; Saidkhodjaeva L; Miettinen M; Wang Y; Pack SD; Giaccone G
J Thorac Oncol; 2014 Apr; 9(4):567-71. PubMed ID: 24736083
[TBL] [Abstract][Full Text] [Related]
11. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.
Weiss J; Sos ML; Seidel D; Peifer M; Zander T; Heuckmann JM; Ullrich RT; Menon R; Maier S; Soltermann A; Moch H; Wagener P; Fischer F; Heynck S; Koker M; Schöttle J; Leenders F; Gabler F; Dabow I; Querings S; Heukamp LC; Balke-Want H; Ansén S; Rauh D; Baessmann I; Altmüller J; Wainer Z; Conron M; Wright G; Russell P; Solomon B; Brambilla E; Brambilla C; Lorimier P; Sollberg S; Brustugun OT; Engel-Riedel W; Ludwig C; Petersen I; Sänger J; Clement J; Groen H; Timens W; Sietsma H; Thunnissen E; Smit E; Heideman D; Cappuzzo F; Ligorio C; Damiani S; Hallek M; Beroukhim R; Pao W; Klebl B; Baumann M; Buettner R; Ernestus K; Stoelben E; Wolf J; Nürnberg P; Perner S; Thomas RK
Sci Transl Med; 2010 Dec; 2(62):62ra93. PubMed ID: 21160078
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer.
Zhang L; Yu H; Badzio A; Boyle TA; Schildhaus HU; Lu X; Dziadziuszko R; Jassem J; Varella-Garcia M; Heasley LE; Kowalewski AA; Ellison K; Chen G; Zhou C; Hirsch FR
J Thorac Oncol; 2015 Jul; 10(7):1083-90. PubMed ID: 26020126
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma.
Weeden CE; Holik AZ; Young RJ; Ma SB; Garnier JM; Fox SB; Antippa P; Irving LB; Steinfort DP; Wright GM; Russell PA; Ritchie ME; Burns CJ; Solomon B; Asselin-Labat ML
Mol Cancer Ther; 2017 Aug; 16(8):1610-1622. PubMed ID: 28611104
[TBL] [Abstract][Full Text] [Related]
14. Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer.
Adachi Y; Watanabe K; Kita K; Kitai H; Kotani H; Sato Y; Inase N; Yano S; Ebi H
Carcinogenesis; 2017 Oct; 38(11):1063-1072. PubMed ID: 28968756
[TBL] [Abstract][Full Text] [Related]
15. FGFR1 overexpression in non-small cell lung cancer is mediated by genetic and epigenetic mechanisms and is a determinant of FGFR1 inhibitor response.
Bogatyrova O; Mattsson JSM; Ross EM; Sanderson MP; Backman M; Botling J; Brunnström H; Kurppa P; La Fleur L; Strell C; Wilm C; Zimmermann A; Esdar C; Micke P
Eur J Cancer; 2021 Jul; 151():136-149. PubMed ID: 33984662
[TBL] [Abstract][Full Text] [Related]
16. FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy.
Quintanal-Villalonga Á; Ferrer I; Guruceaga E; Cirauqui C; Marrugal Á; Ojeda L; García S; Zugazagoitia J; Muñoz-Galván S; Lopez-Rios F; Montuenga L; Vicent S; Molina-Pinelo S; Carnero A; Paz-Ares L
EBioMedicine; 2020 Mar; 53():102683. PubMed ID: 32114392
[TBL] [Abstract][Full Text] [Related]
17. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study.
Lim SH; Sun JM; Choi YL; Kim HR; Ahn S; Lee JY; Lee SH; Ahn JS; Park K; Kim JH; Cho BC; Ahn MJ
Cancer; 2016 Oct; 122(19):3024-31. PubMed ID: 27315356
[TBL] [Abstract][Full Text] [Related]
19. Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.
Raoof S; Mulford IJ; Frisco-Cabanos H; Nangia V; Timonina D; Labrot E; Hafeez N; Bilton SJ; Drier Y; Ji F; Greenberg M; Williams A; Kattermann K; Damon L; Sovath S; Rakiec DP; Korn JM; Ruddy DA; Benes CH; Hammerman PS; Piotrowska Z; Sequist LV; Niederst MJ; Barretina J; Engelman JA; Hata AN
Oncogene; 2019 Sep; 38(37):6399-6413. PubMed ID: 31324888
[TBL] [Abstract][Full Text] [Related]
20. Genomic insights into the mechanisms of FGFR1 dependency in squamous cell lung cancer.
Mäkinen N; Meyerson M
J Clin Invest; 2023 Nov; 133(21):. PubMed ID: 37909331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
